VivoSeq
Other

Aggressive Periodontitis

10

Pipeline Programs

0

Active Trials

3

Companies Involved

Aggressive Periodontitis is an early-stage landscape with 10 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Bayer, AbbVie. 3 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

12

clinical trials

Completed10 · 83%
Unknown status2 · 17%

Trial Activity

12 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)